Shenzhen Kangtai Biological Products Co.,Ltd. (300601.SZ) Signs License Termination Agreement with AstraZeneca

Stock News09-30

Shenzhen Kangtai Biological Products Co.,Ltd. (300601.SZ) announced that on August 20, 2020, the company entered into a License Agreement with AstraZeneca UK Limited (referred to as "AstraZeneca"). Under this agreement, AstraZeneca granted the company exclusive authorization to develop, manufacture, and commercialize the ChAdOx1 adenoviral vector COVID-19 vaccine (referred to as the "licensed product") within the People's Republic of China (excluding Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region).

Given significant changes in domestic and international COVID-19 vaccine prevalent strains and market conditions, both parties have reached a mutual agreement through friendly consultation to terminate the cooperation for the development, manufacturing, and commercialization of the licensed product (ChAdOx1 adenoviral vector COVID-19 vaccine) as stipulated in the License Agreement. The parties recently signed a License Termination Agreement, under which all rights and obligations under the original License Agreement will be terminated effective from the date when the License Termination Agreement is signed and becomes effective by both parties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment